Tag:

Byetta

Latest Headlines

Latest Headlines

Investors pump $200M into Intarcia's PhIII for once-yearly diabetes therapy

For most biotechs, the huge cost of a late-stage diabetes drug program is enough to shut down any discussion about pushing through alone to an approval. Intarcia, though, says it now has the money needed to do just that for new technology billed as a prospective game-changer for one of the world's most prevalent diseases.

Novo's exceptional first quarter still disappoints

When can a drugmaker beat earnings expectations and project a 10% boost in profits for the year and still end up disappointing investors? When that drugmaker is Novo Nordisk, the world's largest insulin maker, focused on a rapidly growing treatment area with investors expecting more, more, more.

Safety watchdog flags GLP-1 drugs for pancreatitis reports to FDA

A safety watchdog group has analyzed the FDA's adverse event data on the entire GLP-1 class of diabetes drugs, finding more reports of pancreatitis and pancreatic cancer for these drugs compared with older treatments.

FDA scrutinizing Merck's Januvia, BMS' Byetta

The FDA is taking a closer look at the increased risk of Type 2 diabetics getting pancreatic cancer from the popular drugs like Merck's blockbuster Januvia and Byetta from Bristol-Myers Squibb.

Januvia, Byetta double pancreatitis risk, JAMA analysis finds

The diabetes treatments Januvia and Byetta may double patients' risk of pancreatitis, a new study finds.

Januvia, Byetta double pancreatitis risk, JAMA analysis finds

The diabetes treatments Januvia and Byetta may double patients' risk of pancreatitis, a new study finds. The drugs, sold by Merck and a Bristol-Myers Squibb/AstraZeneca partnership, have been linked to pancreatitis before, but the JAMA Internal Medicine study puts a number to that risk for the first time.

Novo exec welcomes the Bristol-AZ diabetes blitz

Bristol-Myers Squibb ($BMY) and AstraZeneca ($AZN) dispatching legions of sales reps to tout Byetta and Bydureon? Bring it on, says Novo Nordisk's ($NVO) Mads Krogsgaard Thomsen. The Danish company's chief scientific officer told Bloomberg that more talk about that class of diabetes drugs will help Novo, too.

Sanofi stands up for diabetes therapy in crowded GLP-1 contest

Sanofi is making a case for why its experimental diabetes drug Lyxumia stands out from existing GLP-1 therapies, as the French drug giant eyes the new med to build up its Lantus-led diabetes franchise amid relentless competition.

Bristol-Myers, AZ aim for diabetes glory with Amylin buy

Now that Bristol-Myers Squibb and AstraZeneca have teamed up to buy Amylin Pharmaceuticals, the question is this: Can their Big Pharma sales heft make Amylin's diabetes franchise pay off? Enough to justify the $7 billion outlay?

FDA official: Amylin held back safety data on Byetta

The FDA says Amylin Pharmaceuticals hasn't been completely honest about its diabetes drugs. Actually, a top agency official said so back in January, but the documents were only just posted to the FDA website.